GlassScriptPhysician profile
Enid A Trotman
NPI 1174602619
$961.26
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $154.08 | 2019 | |
| Pfizer INC. | $129.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $97.91 | 2019-2020 | |
| Novo Nordisk INC | $69.28 | 2019 | |
| Scilex Pharmaceuticals INC. | $68.68 | 2019-2020 | |
| Gilead Sciences, INC. | $47.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.66 | 2019 | |
| Allergan, INC. | $39.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $34.45 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $28.12 | 2019 | |
| Astellas Pharma US INC | $17.03 | 2019 | |
| Sanofi Pasteur INC. | $16.05 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.95 | 2019 | |
| Shionogi INC | $13.57 | 2019 | |
| Merck Sharp & Dohme LLC | $10.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $6.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enid Trotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.